AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
procainamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| Class I antiarrhythmics, procainamide and lidocaine derivatives | 2270 | 51-06-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | g | O |
| 3 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Bocci G, Oprea TI, Benet LZ |
| S (Water solubility) | 2 mg/mL | Bocci G, Oprea TI, Benet LZ |
| EoM (Fraction excreted unchanged in urine) | 67 % | Benet LZ, Broccatelli F, Oprea TI |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 81 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 212.47 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 83 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 2.20 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.84 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 3.10 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.872 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.893 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 3.648 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 6.252 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 89.830 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 79.140 | % | High | 1 |
| herg | hERG pIC50 | 4.177 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.992 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.373 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 88.070 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ULK2 | 71 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GAK,GRK2,GRK3,MAPK7,MARK4,NUAK1,PRKCD,SGK1,SIK2,SIK3,STK33,TEK,TTK,ULK1,ULK2 | 26 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.130 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 52.360 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 93.560 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.574 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | High | 1 | |
| pppb | Pig plasma protein binding (% unbound) | 90.790 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 26.182 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 91.300 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 83.560 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 864.968 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 2, 1950 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug ineffective | 138.07 | 76.36 | 64 | 160 | 630133 | 41990978 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Gliosis | 111.37 | 91.72 | 16 | 836 | 716 | 110587731 |
| Ovarian failure | 106.77 | 91.72 | 16 | 836 | 960 | 110587487 |
| Polyserositis | 105.84 | 91.72 | 16 | 836 | 1018 | 110587429 |
| Premature menopause | 105.72 | 91.72 | 16 | 836 | 1026 | 110587421 |
| Pouchitis | 101.03 | 91.72 | 16 | 836 | 1381 | 110587066 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01BA02 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Antiarrhythmics, class Ia |
| FDA EPC | N0000175426 | Antiarrhythmic |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D026941 | Sodium Channel Blockers |
| MeSH PA | D049990 | Membrane Transport Modulators |
| MeSH PA | D061567 | Voltage-Gated Sodium Channel Blockers |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:38633 | sodium channel blocker |
| CHEBI has role | CHEBI:50427 | platelet aggregation inhibitor |
Related Drugs by ATC class:
C01BA Antiarrhythmics, class Ia 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Life-Threatening Ventricular Tachycardia | indication | ||
| Bundle branch block | contraindication | 6374002 | |
| Poisoning by digitalis glycoside | contraindication | 12876009 | |
| Hyperkalemia | contraindication | 14140009 | |
| Agranulocytosis | contraindication | 17182001 | DOID:12987 |
| Complete atrioventricular block | contraindication | 27885002 | |
| Torsades de pointes | contraindication | 31722008 | |
| Hypokalemia | contraindication | 43339004 | |
| Low blood pressure | contraindication | 45007003 | |
| Chronic heart failure | contraindication | 48447003 | |
| Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Prolonged QT interval | contraindication | 111975006 | |
| Second degree atrioventricular block | contraindication | 195042002 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Myocardial infarction in recovery phase | contraindication | 418044006 | |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Procainamide Toxicity | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.0 | acidic |
| pKa2 | 8.94 | Basic |
| pKa3 | 2.36 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium channel alpha subunit | Ion channel | BLOCKER | CHEMBL | CHEMBL | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 3.86 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.81 | PDSP | |||||
| Acetylcholinesterase | Enzyme | Ki | 6 | WOMBAT-PK | |||||
| DNA (cytosine-5)-methyltransferase 3B | Enzyme | WOMBAT-PK | |||||||
| DNA (cytosine-5)-methyltransferase 3A | Enzyme | WOMBAT-PK | |||||||
| DNA (cytosine-5)-methyltransferase 1 | Enzyme | WOMBAT-PK | |||||||
| Acetylcholinesterase | Enzyme | Ki | 6 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019904 | VUID |
| N0000147989 | NUI |
| D00477 | KEGG_DRUG |
| 614-39-1 | SECONDARY_CAS_RN |
| 4017622 | VANDF |
| 4019904 | VANDF |
| C0033216 | UMLSCUI |
| CHEBI:8428 | CHEBI |
| CHEMBL640 | ChEMBL_ID |
| DB01035 | DRUGBANK_ID |
| CHEMBL605 | ChEMBL_ID |
| D011342 | MESH_DESCRIPTOR_UI |
| 4913 | PUBCHEM_CID |
| 4811 | IUPHAR_LIGAND_ID |
| 4179 | INN_ID |
| L39WTC366D | UNII |
| 155056 | RXNORM |
| 5358 | MMSL |
| 6415 | MMSL |
| 792 | MMSL |
| d00075 | MMSL |
| 000622 | NDDF |
| 004481 | NDDF |
| 11959009 | SNOMEDCT_US |
| 25254000 | SNOMEDCT_US |
| 372589008 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1902 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-900 | INJECTION | 500 mg | INTRAMUSCULAR | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-901 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-322 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 23 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-323 | INJECTION, SOLUTION | 500 mg | INTRAVENOUS | ANDA | 23 sections |
| PROCAINAMIDE HCI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1334 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | ANDA | 13 sections |
| PROCAINAMIDE HCI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1392 | INJECTION, SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 13 sections |
| PROCAINAMIDE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1630 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 13 sections |
| Procainamide Hydrochloride | Human Prescription Drug Label | 1 | 65145-155 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | ANDA | 21 sections |
| Procainamide Hydrochloride | Human Prescription Drug Label | 1 | 65145-156 | INJECTION, SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 21 sections |
| Procainamide Hydrochloride | Human Prescription Drug Label | 1 | 68083-603 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Procainamide Hydrochloride | Human Prescription Drug Label | 1 | 68083-604 | INJECTION, SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 12 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-4208 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7113 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7115 | INJECTION | 1000 mg | INTRAVENOUS | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7170 | INJECTION | 1000 mg | INTRAVENOUS | ANDA | 22 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7353 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 23 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76329-3399 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 21 sections |
| Procainamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 84549-399 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 21 sections |